Literature DB >> 26111151

PharmGKB summary: peginterferon-α pathway.

Scott R Shuldiner1, Li Gong, Andrew J Muir, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26111151      PMCID： PMC4757589          DOI： 10.1097/FPC.0000000000000158

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  132 in total

1.  Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Authors:  Chen-Hua Liu; Cheng-Chao Liang; Chun-Jen Liu; Tai-Chung Tseng; Chih-Lin Lin; Sheng-Shun Yang; Tung-Hung Su; Shih-Jer Hsu; Jou-Wei Lin; Jun-Herng Chen; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Antivir Ther       Date:  2011-12-20

2.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

Review 3.  Host genomics and HCV treatment response.

Authors:  Paul J Clark; Alexander J Thompson
Journal:  J Gastroenterol Hepatol       Date:  2012-02       Impact factor: 4.029

4.  A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

Authors:  Marcelo Silva; Jorge Poo; Frank Wagner; Mary Jackson; David Cutler; Michael Grace; Ronald Bordens; Connie Cullen; Joann Harvey; Mark Laughlin
Journal:  J Hepatol       Date:  2006-04-18       Impact factor: 25.083

5.  The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables.

Authors:  Andres Duarte-Rojo; Bart J Veldt; David D Goldstein; Hans L Tillman; Kymberly D Watt; Julie K Heimbach; John G McHutchison; John J Poterucha; Florencia Vargas-Vorackova; Michael R Charlton
Journal:  Transplantation       Date:  2012-07-27       Impact factor: 4.939

6.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

7.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

8.  Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.

Authors:  Arne Nørgaard Eskesen; Espen Melum; Amir Moghaddam; Kristian Bjøro; Hans Verbaan; Helmer Ring-Larsen; Olav Dalgard
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-08       Impact factor: 2.566

9.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin.

Authors:  D Maag; C Castro; Z Hong; C E Cameron
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.